• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Study on Nalmefene, Naloxone for Fentanyl Respiratory Depression

    BUSINESSWIRE

    FDA Approves First Nalmefene Hydrochloride Auto-Injector

    FDA

    FDA Approves Zurnai Auto-Injector For Emergency Opioid Overdose Treatment

    BUSINESSWIRE

    FDA Accepts Filing of NDA for Nalmefene for the Treatment of Opioid Overdose

    BUSINESSWIRE

    Purdue Awards Grant for to Examine Opioid Overdose Reversal Using Nalmefene HCl

    BUSINESSWIRE

    Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

    PR NEWSWIRE

    FDA approves another new type of opioid overdose antidote nasal spray

    ENDPTS

    Indivior Announces U.S. FDA Approval of OPVEE Nasal Spray

    PR NEWSWIRE

    FDA Grants Priority Review for Nalmefene Prefilled Syringe for Opioid Overdose

    BUSINESSWIRE

    FDA Clears Titan`s IND Application for Nalmefene Implant

    PRNEWSWIRE

    Purdue Pharma Introduces Nalmefene HCl Injection, 2mg/2mL in U.S.

    BUSINESSWIRE

    Opiant, Aptar Pharma Expand Long-Term Collaboration for OPNT003, Nasal Nalmefene

    GLOBENEWSWIRE

    Opiant Pharma Shows Topline Results Comparing Nasal Nalmefene to Nasal Naloxone

    GLOBENEWSWIRE

    FDA Approves Nalmefene HCl Injection for Opioid Overdose

    BUSINESSWIRE

    Purdue Pharma`s Generic Nalmefene Hydrochloride Receives Approval in the U.S.

    FDA

    FDA Grants Priority Review for Nalmefene HCI Injection

    BUSINESSWIRE

    FDA Accepts Filing of ANDA & Grants Priority Review for Nalmefene HCI Injection

    BUSINESSWIRE

    Opiant Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment

    GLOBENEWSWIRE

    Positive Results from Human PK Study Assessing Orexo`s Intranasal Nalmefene

    PRNEWSWIRE

    FDA to Speed Review of Generic Versions of Opioid Overdose Antidote

    RAPS

    FDA Grants CGT Designation to Purdue`s Investigational Nalmefene HCl Injection

    BUSINESSWIRE

    Purdue Pharma vow not to profit from fast tracked opioid overdose antidote

    PHARMA FILE

    FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation

    BUSINESSWIRE

    Opiant Gets BARDA Grant For Intranasal Opioid Antagonist

    BIOCENTURY

    Titan Awarded NIDA Grant For Nalmefene Implant against Opioid Addiction Relapse

    PR NEWSWIRE

    Determination That REVEX (Nalmefene Hydrochloride Injection), 0.1 Milligram Base

    FEDERAL REGISTER

    Biotie Announces Top-Line Results From Nepicastat (SYN117) Study in Cocaine Dependence

    BIOTIE THERAPIES

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.